Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE + Fludarabine vs Rituximab + Fludarabine in Follicular Lymphoma
NCT00850499Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Sep 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of bortezomib in follicular lymphoma (FL) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Complete Response Rate. Started Sep 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00850499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850499.